Table: q1_q4_2019_prescription_drugs_intro_to_market , manufacturer_name like J*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Janssen	50458002802	SPRAVATO Estekamine Nasal Spray 56mg (2X28mg)	2019-03-08	590.0000	While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising in the mental health community, as well as promoting to appropriate healthcare professionals, systems of care and behavioral health clinics who treat individuals living with treatment resistant depression. The pricing plan has WAC set at $590 per package of 2 inhalers. The list price of SPRAVATO™ is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. SPRAVATO™ will also be discounted as required under the 340B program, the Federal Supply Schedule, and other government programs. Internationally, we are pursuing regulatory approvals for SPRAVATO for the treatment of treatment resistant depression. No approvals have been granted at this time.	None	None	1	1	None	None	None	None	While Janssen's estimated volume of patients who may be prescribed SPRAVATO is not available in the public domain, according to the National Institute of Mental Health, there are approximately 16.2 million patients with major depressive disorder (MDD) in the United States, and approximately 1/3 of MDD patients have treatment resistant depression (TRD). SPRAVATO will be clinically appropriate for a subset of patients with TRD.	None
Janssen	50458002803	SPRAVATO Estekamine Nasal Spray 84mg (3X28mg)	2019-03-08	885.0000	While specific marketing and pricing plans are not available in the public domain, generally we are marketing in the US with print distribution and digital advertising in the mental health community, as well as promoting to appropriate healthcare professionals, systems of care and behavioral health clinics who treat individuals living with treatment resistant depression. The pricing plan has WAC set at $885 per package of 3 inhalers. The list price of SPRAVATO™ is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. SPRAVATO™ will also be discounted as required under the 340B program, the Federal Supply Schedule, and other government programs. Internationally, we are pursuing regulatory approvals for SPRAVATO for the treatment of treatment resistant depression. No approvals have been granted at this time.	None	None	1	1	None	None	None	None	While Janssen's estimated volume of patients who may be prescribed SPRAVATO is not available in the public domain, according to the National Institute of Mental Health, there are approximately 16.2 million patients with major depressive disorder (MDD) in the United States, and approximately 1/3 of MDD patients have treatment resistant depression (TRD). SPRAVATO will be clinically appropriate for a subset of patients with TRD.	None
Janssen	59676003056	BALVERSA Erdafitinib 3mg 56 tablets	2019-04-15	15120.0000	While specific marketing and pricing plans are not available in the public domain, generally we plan to market in the US and promote to appropriate healthcare professionals who treat individuals living with metastatic urothelial cancer (mUC). The pricing plan has WAC set for 3mg 56 tablets at $15,120.00. The list price of BALVERSA is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. BALVERSA will also be discounted as required under the Federal Supply Schedule, and other government programs. There are no International approvals for BALVERSA.	None	None	1	1	None	None	None	None	While Janssen's estimated volume of patients who may be prescribed BALVERSA is not available in the public domain, BALVERSA is approved specifically for the treatment of patients with locally mUC harboring FGFR3 or FGFR2 genetic alterations. In the U.S., it is estimated that up to 3,000 people with urothelial carcinoma will test FGFR positive on an annual basis. Balversa was developed by Janssen.	None
Janssen	59676003084	BALVERSA Erdafitinib 3mg 84 tablets	2019-04-15	22680.0000	While specific marketing and pricing plans are not available in the public domain, generally we plan to market in the US and promote to appropriate healthcare professionals who treat individuals living with metastatic urothelial cancer (mUC). The pricing plan has WAC set for 3mg 84 tablets at $22,680.00. The list price of BALVERSA is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. BALVERSA will also be discounted as required under the Federal Supply Schedule, and other government programs. There are no International approvals for BALVERSA.	None	None	1	1	None	None	None	None	While Janssen's estimated volume of patients who may be prescribed BALVERSA is not available in the public domain, BALVERSA is approved specifically for the treatment of patients with locally mUC harboring FGFR3 or FGFR2 genetic alterations. In the U.S., it is estimated that up to 3,000 people with urothelial carcinoma will test FGFR positive on an annual basis. Balversa was developed by Janssen.	None
Janssen	59676004028	BALVERSA Erdafitinib 4mg 28 tablets	2019-04-15	10080.0000	While specific marketing and pricing plans are not available in the public domain, generally we plan to market in the US and promote to appropriate healthcare professionals who treat individuals living with metastatic urothelial cancer (mUC). The pricing plan has WAC set for 4mg 28 tablets at $10,080.00. The list price of BALVERSA is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. BALVERSA will also be discounted as required under the Federal Supply Schedule, and other government programs. There are no International approvals for BALVERSA.	None	None	1	1	None	None	None	None	While Janssen's estimated volume of patients who may be prescribed BALVERSA is not available in the public domain, BALVERSA is approved specifically for the treatment of patients with locally mUC harboring FGFR3 or FGFR2 genetic alterations. In the U.S., it is estimated that up to 3,000 people with urothelial carcinoma will test FGFR positive on an annual basis. Balversa was developed by Janssen.	None
Janssen	59676004056	BALVERSA Erdafitinib 4mg 56 tablets	2019-04-15	20160.0000	While specific marketing and pricing plans are not available in the public domain, generally we plan to market in the US and promote to appropriate healthcare professionals who treat individuals living with metastatic urothelial cancer (mUC). The pricing plan has WAC set for 4mg 56 tablets at $20,160.00. The list price of BALVERSA is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. BALVERSA will also be discounted as required under the Federal Supply Schedule, and other government programs. There are no International approvals for BALVERSA.	None	None	1	1	None	None	None	None	While Janssen's estimated volume of patients who may be prescribed BALVERSA is not available in the public domain, BALVERSA is approved specifically for the treatment of patients with locally mUC harboring FGFR3 or FGFR2 genetic alterations. In the U.S., it is estimated that up to 3,000 people with urothelial carcinoma will test FGFR positive on an annual basis. Balversa was developed by Janssen.	None
Janssen	59676005028	BALVERSA Erdafitinib 5mg 28 tablets	2019-04-15	12600.0000	While specific marketing and pricing plans are not available in the public domain, generally we plan to market in the US and promote to appropriate healthcare professionals who treat individuals living with metastatic urothelial cancer (mUC). The pricing plan has WAC set for 5mg 28 tablets at $12,600.00. The list price of BALVERSA is not reflective of discounts and rebates which may be available through Medicaid, Medicare, and commercial insurance. BALVERSA will also be discounted as required under the Federal Supply Schedule, and other government programs. There are no International approvals for BALVERSA.	None	None	1	1	None	None	None	None	While Janssen's estimated volume of patients who may be prescribed BALVERSA is not available in the public domain, BALVERSA is approved specifically for the treatment of patients with locally mUC harboring FGFR3 or FGFR2 genetic alterations. In the U.S., it is estimated that up to 3,000 people with urothelial carcinoma will test FGFR positive on an annual basis. Balversa was developed by Janssen.	None